Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446912 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
A Phase 3 study of Active Systemic Lupus Erythematosus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 20
- Study locations
NCT02446912 is a Phase 3 study of Active Systemic Lupus Erythematosus that has completed, run by AstraZeneca. The registered enrollment target is 460 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT02446912, a Phase 3 study of Active Systemic Lupus Erythematosus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Anifrolumab
Study Locations (20)
Florida
- Research Site - Aventura
- Research Site - Miami
- Research Site - Orlando
- Research Site - Orlando
- Research Site - Ormond Beach
- Research Site - Plantation
- Research Site - Tampa
- Research Site - Vero Beach
California
- Research Site - El Cajon
- Research Site - La Jolla
- Research Site - Los Alamitos
- Research Site - Thousand Oaks
Georgia
- Research Site - Decatur
- Research Site - Lawrenceville
- Research Site - Marietta
Idaho
- Research Site - Boise
- Research Site - Idaho Falls
Alabama
- Research Site - Birmingham
Colorado
- Research Site - Aurora
Louisiana
- Research Site - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446912
The ClinicalTrials.gov registry entry for NCT02446912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02446912 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02446912 about?
NCT02446912 is a clinical study titled "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
What is the current status of trial NCT02446912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2015-06-09. Estimated completion is 2018-07-17.
What conditions does trial NCT02446912 study?
This clinical trial studies the following conditions: Active Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT02446912?
The interventions under investigation include: Placebo (DRUG), Anifrolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02446912?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02446912 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.